within Pharmacolibrary.Drugs.ATC.J;

model J05AH03
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00016833333333333332,
    adminDuration  = 600,
    adminMass      = 600 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.01256,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00813,
    k12             = 16.6,
    k21             = 16.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AH03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Peramivir is a neuraminidase inhibitor antiviral drug used for the treatment of influenza. It is administered primarily as a single-dose intravenous infusion for adults with acute uncomplicated influenza. Peramivir is approved for use in the United States and several other countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects after a single 600 mg intravenous dose.</p><h4>References</h4><ol><li><p>Zhang, D, et al., &amp; Liu, H (2015). Pharmacokinetics of peramivir after single intravenous doses in healthy Chinese subjects. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 45(3) 239–243. DOI:<a href=\"https://doi.org/10.3109/00498254.2014.960907\">10.3109/00498254.2014.960907</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25231091/\">https://pubmed.ncbi.nlm.nih.gov/25231091</a></p></li><li><p>Saisho, Y, et al., &amp; Shimada, J (2017). Pharmacokinetics and safety of intravenous peramivir, neuraminidase inhibitor of influenza virus, in healthy Japanese subjects. <i>Antiviral therapy</i> 22(4) 313–323. DOI:<a href=\"https://doi.org/10.3851/IMP3104\">10.3851/IMP3104</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27805571/\">https://pubmed.ncbi.nlm.nih.gov/27805571</a></p></li><li><p>Funatsu, Y, et al., &amp; Hasegawa, N (2016). Pharmacokinetics of intravenous peramivir in the airway epithelial lining fluid of healthy volunteers. <i>Antiviral therapy</i> 21(7) 621–625. DOI:<a href=\"https://doi.org/10.3851/IMP3096\">10.3851/IMP3096</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27694694/\">https://pubmed.ncbi.nlm.nih.gov/27694694</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AH03;
